Results 11 to 20 of about 339,213 (296)
Antibody drug conjugates [PDF]
Indian Journal of Medical and Paediatric Oncology, 2020 Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released,
Stalin Bala, Siva K Prasad
doaj +5 more sources
Antibody–drug conjugates [PDF]
Proceedings of the National Academy of Sciences, 2013 Ideally, targeted therapies attack diseased cells while leaving healthy ones alone. It’s a strategy that could result in more effective treatments for cancer (or other diseases) with fewer toxic side effects than traditional chemotherapies. A burgeoning class of targeted therapies, called antibody–drug conjugates (ADC), deliver dual therapies in a ...
Rachel S. Zolot +2 more
+12 more sources
Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates [PDF]
Journal of Clinical Medicine, 2021 A summary of the key technological advancements in the preparation of antibody–oligonucleotide conjugates (AOCs) and the distinct advantages and disadvantages of AOCs as novel therapeutics are presented. The merits and demerits of the different approaches to conjugating oligonucleotides to antibodies, antibody fragments or other proteins, mainly from ...
Julien Dugal-Tessier +2 more
openaire +2 more sources
Antibody–Drug Conjugates [PDF]
Bioconjugate Chemistry, 2015 Antibody-drug conjugates (ADCs) are an exciting and new class of therapeutic modalities that have gained significant traction over the past few years – specifically in the field of oncology. With the recent approvals of CD-30 directed Adcetris® (brentuximab vedotin) and the Her2 targeted Kadcyla® (ado-trastuzumab emtansine) and hundreds of other ADCs ...
Li Peng, Xiaoyuan Chen
openaire +5 more sources
Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate
Pharmaceutics, 2022 As one of the major therapeutic options for cancer treatment, chemotherapy has limited selectivity against cancer cells. Consequently, this therapeutic strategy offers a small therapeutic window with potentially high toxicity and thus limited efficacy of
Rotimi Sheyi +2 more
semanticscholar +1 more source
Blood, 2022 In this Blood Spotlight, Calabretta and colleagues describe the mechanism of action of loncastuximab tesirine, an anti-CD19 antibody-drug conjugate. They discuss data from the first phase 1 and 2 trials of the drug in patients with relapsed or refractory
Eleonora Calabretta +2 more
semanticscholar +1 more source
Introduction to Antibody-Drug Conjugates [PDF]
Antibodies, 2021 Antibody-drug conjugates (ADCs) are innovative biopharmaceutical products in which a monoclonal antibody is linked to a small molecule drug with a stable linker. Most of the ADCs developed so far are for treating cancer, but there is enormous potential for using ADCs to treat other diseases.
openaire +3 more sources
Molecular Cancer Therapeutics, 2021 Trophoblast cell surface antigen 2 (TROP2) is highly expressed on various epithelial tumors and correlates with poor prognosis. We developed the novel TROP2-directed antibody–drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd, DS-1062a), with a ...
D. Okajima +22 more
semanticscholar +1 more source
Nature Communications, 2023 Poor renal distribution of antibody-based drugs is the key factor contributing to low treatment efficiency for renal diseases and side effects. Here, we prepare F(ab′)2 fragmented vascular endothelial growth factor receptor 2 antibody (anti-VEGFR2 (F(ab′)
Di Liu +12 more
doaj +1 more source
Scientific Reports, 2021 A wide range of diseases have been shown to be influenced by the accumulation of senescent cells, from fibrosis to diabetes, cancer, Alzheimer’s and other age-related pathologies.
M. Poblocka +10 more
semanticscholar +1 more source